CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation
Our study presents the first in vivo evidence that CD2AP deficiency exacerbates the phenotypes and pathology of AD through the p38 MAPK pathway, identifying CD2AP/p38 MAPK as promising therapeutic targets for AD.
Authors
- Z. Zhang
- Zhi‐Ying Wu (ORCID: https://orcid.org/0000-0003-2106-572X)
- Hui-Fen Huang (ORCID: https://orcid.org/0000-0003-1643-1182)
- Dian-Fu Chen (ORCID: https://orcid.org/0000-0002-0571-2598)
- Keqing Zhu (ORCID: https://orcid.org/0000-0003-2864-3043)
- Qing‐Qing Tao (ORCID: https://orcid.org/0000-0002-3318-1747)
- Yan‐Yan Xue
- Rong-Rong Lin
Institutions
- Allen Institute for Brain Science (US)
- Center for Excellence in Brain Science and Intelligence Technology (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Translational Neurodegeneration
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1186/s40035-024-00454-5
- Citations
- 14
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 3.46
Funders
- National Natural Science Foundation of China